Will brensocatib receive FDA approval for non-cystic fibrosis bronchiectasis by the end of 2024? | Binary | | | 7 months ago | |
Will Insmed's market cap reach $10 billion by the end of 2024? | Binary | | | 7 months ago | |
Will Insmed expand brensocatib trials to additional indications by mid-2025? | Binary | | | 7 months ago | |
What will be the next major development phase for brensocatib by the end of 2025? | Categorical | | | 7 months ago | |
Annual global sales of Brensocatib two years after market launch | Categorical | | | 7 months ago | |
Will Brensocatib receive FDA approval for bronchiectasis by end of 2024? | Binary | | | 7 months ago | |
What will be the global sales of brensocatib within one year post-approval? | Categorical | | | 7 months ago | |
How will Insmed's stock price perform by the end of 2024? | Categorical | | | 7 months ago | |
Will Brensocatib be licensed for marketing outside the US by end of 2024? | Binary | | | 7 months ago | |
Insmed's share price range on the first trading day after FDA approval of Brensocatib | Categorical | | | 7 months ago | |
Number of new approved indications for Brensocatib within five years | Categorical | | | 7 months ago | |
Will Insmed's market cap reach $10 billion due to Brensocatib by mid-2025? | Binary | | | 7 months ago | |
